Intuitive announces Dave Rosa's promotion to CEO, with Gary Guthart transitioning to executive chair and Craig Barratt as lead independent director.
Quiver AI Summary
Intuitive, a leader in minimally invasive care and robotic-assisted surgery, has announced the promotion of President Dave Rosa to CEO, effective July 1, 2025. Current CEO Gary Guthart will transition to become the executive chair of the board, while Craig Barratt will take on the role of lead independent director. The board emphasized Rosa's significant contributions in shaping the company's strategy and product development, making him well-suited to lead Intuitive into its next growth phase. Rosa, who has been with the company since 1996, expressed his commitment to enhancing patient outcomes and access to care while lowering treatment costs. Guthart acknowledged the positive impact of his leadership over the past 15 years, and both he and Rosa are focused on ensuring a smooth leadership transition as Intuitive celebrates its 30th anniversary.
Potential Positives
- Promotion of Dave Rosa to CEO signals a successful and thoughtful succession plan, ensuring stability in leadership.
- Rosa's extensive 29-year experience with Intuitive, including key roles in product development and strategy, positions him to effectively drive the company's growth.
- Continuation of Gary Guthart's involvement as executive chair allows for a seamless transition while retaining leadership continuity and expertise.
- The announcement coincides with the company's 30th anniversary, highlighting a long history of innovation and commitment to improving patient outcomes in robotic-assisted surgery.
Potential Negatives
- Transitioning leadership can create uncertainty among employees and investors, potentially impacting company stability and performance during the changeover.
- Reports of a significant change in executive leadership may raise concerns regarding the company's strategic direction and continuity, particularly as the outgoing CEO had a long tenure.
- Forward-looking statements highlight inherent risks and uncertainties, which could negatively influence market perceptions and investor confidence in the company's future performance.
FAQ
Who has been promoted to CEO of Intuitive?
Dave Rosa has been promoted to the position of CEO, effective July 1, 2025.
What position will Gary Guthart assume after stepping down as CEO?
Gary Guthart will become the executive chair of Intuitive’s board of directors.
How long has Dave Rosa been with Intuitive?
Dave Rosa has been with Intuitive for 29 years, joining the company in March 1996.
What is Intuitive's main focus in healthcare?
Intuitive specializes in minimally invasive care and is a pioneer in robotic-assisted surgery.
What advancements has Intuitive achieved in its history?
Intuitive has facilitated nearly 17 million da Vinci procedures and trained around 90,000 surgeons globally.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ISRG Congressional Stock Trading
Members of Congress have traded $ISRG stock 8 times in the past 6 months. Of those trades, 2 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $ISRG stock by members of Congress over the last 6 months:
- REPRESENTATIVE BRUCE WESTERMAN has traded it 2 times. They made 1 purchase worth up to $15,000 on 03/03 and 1 sale worth up to $15,000 on 04/21.
- REPRESENTATIVE JEFFERSON SHREVE sold up to $50,000 on 04/07.
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 01/30.
- REPRESENTATIVE JOSH GOTTHEIMER has traded it 4 times. They made 0 purchases and 4 sales worth up to $60,000 on 01/29, 01/21, 01/10, 12/23.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$ISRG Insider Trading Activity
$ISRG insiders have traded $ISRG stock on the open market 70 times in the past 6 months. Of those trades, 0 have been purchases and 70 have been sales.
Here’s a breakdown of recent trading of $ISRG stock by insiders over the last 6 months:
- DAVID J. ROSA (President) has made 0 purchases and 2 sales selling 16,509 shares for an estimated $9,204,142.
- ROBERT DESANTIS (EVP & Chief Strategy & Corp Op) has made 0 purchases and 18 sales selling 13,307 shares for an estimated $6,689,314.
- BRIAN EDWARD MILLER (EVP & Chief Digital Officer) has made 0 purchases and 5 sales selling 12,900 shares for an estimated $6,365,341.
- MYRIAM CURET (EVP & Chief Medical Officer) has made 0 purchases and 4 sales selling 9,840 shares for an estimated $5,438,101.
- JAMIE SAMATH (See Remarks) has made 0 purchases and 21 sales selling 9,028 shares for an estimated $5,123,629.
- AMY L LADD has made 0 purchases and 6 sales selling 8,926 shares for an estimated $4,521,660.
- AMAL M JOHNSON sold 4,635 shares for an estimated $2,626,191
- GARY LOEB (EVP & Chief Legal and Complian) has made 0 purchases and 3 sales selling 4,300 shares for an estimated $2,390,260.
- MARK BROSIUS (SVP & Chief Mfg and Supply Cha) has made 0 purchases and 8 sales selling 2,523 shares for an estimated $1,404,901.
- JAMI K NACHTSHEIM sold 2,400 shares for an estimated $1,248,000
- FREDRIK WIDMAN (VP Corporate Controller) sold 810 shares for an estimated $464,761
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ISRG Hedge Fund Activity
We have seen 1,093 institutional investors add shares of $ISRG stock to their portfolio, and 874 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO removed 1,576,385 shares (-15.5%) from their portfolio in Q1 2025, for an estimated $780,736,198
- GQG PARTNERS LLC removed 1,145,300 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $567,232,731
- FMR LLC removed 1,089,681 shares (-10.1%) from their portfolio in Q1 2025, for an estimated $539,686,308
- PROFICIO CAPITAL PARTNERS LLC removed 948,095 shares (-99.8%) from their portfolio in Q1 2025, for an estimated $469,563,010
- FISHER ASSET MANAGEMENT, LLC removed 821,665 shares (-16.9%) from their portfolio in Q1 2025, for an estimated $406,946,024
- PRICE T ROWE ASSOCIATES INC /MD/ removed 686,369 shares (-4.7%) from their portfolio in Q1 2025, for an estimated $339,937,974
- BAILLIE GIFFORD & CO removed 608,415 shares (-16.1%) from their portfolio in Q1 2025, for an estimated $301,329,697
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ISRG Analyst Ratings
Wall Street analysts have issued reports on $ISRG in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 04/23/2025
- BTIG issued a "Buy" rating on 04/14/2025
- UBS issued a "Overweight" rating on 01/29/2025
- Citigroup issued a "Buy" rating on 01/24/2025
- Morgan Stanley issued a "Overweight" rating on 01/16/2025
- Bernstein issued a "Outperform" rating on 01/08/2025
To track analyst ratings and price targets for $ISRG, check out Quiver Quantitative's $ISRG forecast page.
$ISRG Price Targets
Multiple analysts have issued price targets for $ISRG recently. We have seen 4 analysts offer price targets for $ISRG in the last 6 months, with a median target of $622.5.
Here are some recent targets:
- Ryan Zimmerman from BTIG set a target price of $560.0 on 04/14/2025
- An analyst from Truist Financial set a target price of $605.0 on 03/17/2025
- Patrick Wood from Morgan Stanley set a target price of $650.0 on 12/02/2024
Full Release
President Dave Rosa promoted to CEO
Current CEO Gary Guthart to become executive chair of Intuitive’s board
Current Board Chair Craig Barratt to become lead independent director
SUNNYVALE, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced the promotion of President Dave Rosa to chief executive officer, effective July 1, 2025. At that time, current CEO Gary Guthart will become the executive chair of Intuitive’s board of directors, and current Board Chair Craig Barratt will become lead independent director. Guthart will work closely with Rosa to support a smooth transition and will remain with Intuitive in a senior advisory capacity.
“Dave’s appointment as CEO is the culmination of the Board’s thoughtful succession planning, reflecting his instrumental role in establishing our strategy, guiding the development of our product pipeline, and expanding the company’s global footprint. We are confident he’s the right leader to drive the company’s next chapter of growth,” said Intuitive Board Chair Craig Barratt.
“On behalf of Intuitive’s board, we thank Gary for his leadership of our company. We are fortunate that he will continue to play an important role as our next executive chair,” continued Barratt. “And, on behalf of our customers, we thank him for the role he has played in helping Intuitive pioneer advancements in robotic-assisted surgery that optimize care and deliver better patient outcomes.”
“It has been an honor and a privilege to serve as Intuitive’s CEO for the past 15 years, working alongside our talented and dedicated employees as we seek to advance minimally invasive care for healthcare teams and their patients around the world. Together, we’ve developed products and services that have made a positive difference for care teams and millions of their patients,” said Guthart.
“Having worked closely with Dave for decades, I am confident that his patients-first focus and deep capability in guiding Intuitive’s strategy, our designs, our product and service quality, and our operational excellence make him uniquely qualified to lead our business forward,” said Guthart.
“Gary’s stewardship of Intuitive has had a significant impact on patients, clinicians, and hospitals. I thank him for his work and am honored to become the next Intuitive CEO,” said Rosa.
“We are at an exciting time with a significant opportunity to advance the work that customers care most about—the Quintuple Aim—improving patient outcomes, enhancing patient and care team experience, expanding patient access to care, and ultimately lowering the total cost to treat. I look forward to building on this work alongside the entire Intuitive team to deliver on these goals and drive value for all our stakeholders,” said Rosa.
A 29-year veteran with Intuitive, Rosa first joined the company as its ninth employee in March 1996. Since then, he has held leadership positions across the business, including engineering, clinical and product development, marketing, regulatory and quality affairs, and the commercial organization.
Among his achievements, Rosa founded Intuitive’s first clinical engineering and endoluminal groups, leading to the development and commercialization of the da Vinci SP (single port) robotic-assisted surgical system and Ion robotic bronchoscopy system. He also launched the company’s Future Forward group, which identifies and develops transformational new business opportunities.
Rosa assumed the role of executive vice president and chief business officer in 2019, transitioning to chief strategy and growth officer three years later. Rosa has served as Intuitive’s president since 2023 and became a member of the board of directors in 2024.
2025 marks Intuitive’s 30 th year developing robotic-assisted technology with the goal of improving patient outcomes, improving patient and care team experience, increasing access to minimally invasive care, and lowering the total cost to treat. In Intuitive's first three decades, surgeons performed nearly 17 million da Vinci procedures, and nearly 90,000 surgeons have been trained to use Intuitive’s systems.
Contact: Peper Long, Intuitive
Global Public Affairs
[email protected]
1-202-997-7373
About Intuitive
Intuitive (NASDAQ: ISRG), headquartered in Sunnyvale, California, is a global leader in minimally invasive care and the pioneer of robotic surgery. Our technologies include the da Vinci surgical system and the Ion endoluminal system. By uniting advanced systems, progressive learning, and value-enhancing services, we help physicians and their teams optimize care delivery to support the best outcomes possible. At Intuitive, we envision a future of care that is less invasive and profoundly better, where disease is identified early and treated quickly, so that patients can get back to what matters most.
Forward-Looking Statements
This press release contains forward-looking statements which relate to expectations concerning matters that are not historical facts. Statements using words such as “estimates,” “projects,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “may,” “will,” “can,” “could,” “should,” “would,” “targeted,” “potential,” and similar words and expressions are intended to identify forward-looking statements. These forward-looking statements are necessarily estimates reflecting the judgment of Intuitive’s management and involve a number of risks and uncertainties that could cause actual results or impacts on its operations, financial performance, and business position to differ materially from those suggested by the forward-looking statements. These forward-looking statements include, but are not limited to, statements related to research and development of products and services, manufacturing of products, obtaining of regulatory approvals, technical and other performance of products and services, and making products and services available to more patients and health care professionals. These forward-looking statements should be considered in light of various important factors and involve known and unknown risks, uncertainties, and other factors, which may cause the actual results, performance, or achievements of Intuitive, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements include, among others, economic conditions in the geographic markets in which we operate, changes in governmental regulations, regulatory approval priorities, resources, and timelines, regulatory enforcement priorities, governmental investigations and civil litigation, and other factors discussed in Intuitive’s Annual Reports and other filings with relevant securities regulators.
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release and which are based on current expectations and are subject to risks, uncertainties, and assumptions that are difficult to predict, including those risk factors identified under the heading “Risk Factors” in Intuitive’s Annual Report on Form 10-K for the year ended December 31, 2024, as updated by its other filings with the U.S. Securities and Exchange Commission. Intuitive’s actual results may differ materially and adversely from those expressed in any forward-looking statements, and it undertakes no obligation to publicly update or release any revisions to these forward-looking statements, except as required by law.